Delpharm

Delpharm

Private
Boulogne-BillancourtHealthcare & Life Scienceshttps://delpharm.com

Last Round

Grant

Mar 18, 2025

Total Funding Raised

$94.87M

Company Overview

Delpharm is a pharmaceutical company that provides contract development and manufacturing services for medicines.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Pharma Supply Chain, Quality Management

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

contract development and manufacturing organizationCDMOpharmaceutical manufacturingpharma outsourcingdrug development servicesclinical batch manufacturingsolid dosage manufacturingsterile liquid manufacturingregulatory affairs servicespharmaceutical packagingAPI sourcinggeneric drug manufacturingOTC manufacturingsupply chain servicesserialization services

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Delpharm Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Delpharm Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
GrantMar 18, 2025
DebtJan 31, 2024
GrantAug 26, 2023
DebtSep 17, 2021
GrantJun 14, 2021
Buyout/LBO
Feb 9, 2016

Key People

Founding team and executive leadership

Nicolas Ragot

Chief Executive Officer

Executive Team

Youssef El Hariri

Chief Financial Officer

Executive Team

Nicolas Leforestier

Chief Operating Officer

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 1, 2026

    Annual production capacity exceeds 1 billion boxes of medicine.

  • Mar 1, 2026

    Recognized as a top 5 global contract drug manufacturer.

Delpharm Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Delpharm Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Delpharm's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoulogne-Billancourt
Employee Range3,815
Year Founded1988
Last FundingMar 18, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.